Seizure reduction in TSC2-mutant mouse model by an mTOR catalytic inhibitor.
Dhamne SC, Modi ME, Gray A, Bonazzi S, Craig L, Bainbridge E, Lalani L, Super CE, Schaeffer S, Capre K, Lubicka D, Liang G, Burdette D, McTighe SM, Gurnani S, Vermudez SAD, Curtis D, Wilson CJ, Hameed MQ, D'Amore A, Rotenberg A, Sahin M.
Dhamne SC, et al.
Ann Clin Transl Neurol. 2023 Oct;10(10):1790-1801. doi: 10.1002/acn3.51868. Epub 2023 Aug 6.
Ann Clin Transl Neurol. 2023.
PMID: 37545094
Free PMC article.
RESULTS: Our results show that chronic treatment with this novel mTOR catalytic inhibitor (TC1), which affects both the mTORC1 and mTORC2 signaling complexes, reduces seizure burden, and extends the survival of Tsc2 hypomorphic mice, restoring species typical weight gain o …
RESULTS: Our results show that chronic treatment with this novel mTOR catalytic inhibitor (TC1), which affects both the mTORC1 and mTORC2 si …